Dataset from A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007685
下载链接
链接失效反馈官方服务：
资源简介：
Primary:
- To demonstrate that capecitabine/oxaliplatin as adjuvant chemotherapy is superior to
observation alone in terms of 3 year disease-free survival (DFS) rate in
chemotherapy-naïve patients who underwent potentially curative resection for gastric
cancer.
Secondary:
- To compare the overall survival of surgery and capecitabine/ oxaliplatin as adjuvant
therapy versus surgery alone. To evaluate the safety profile of capecitabine/oxaliplatin
adjuvant therapy.
创建时间：
2024-11-26
